Ceriello A, Falleti E, Motz E, Taboga C, Tonutti L, Ezsol Z, Gonano F, Bartoli E
Dept. of Clinical and Experimental Pathology and Medicine, University of Udine, Italy.
Horm Metab Res. 1998 Mar;30(3):146-9. doi: 10.1055/s-2007-978854.
ICAM-1 is one of the most important intercellular adhesion molecules involved in atherogenesis. Previous studies reported increased circulating ICAM-1 plasma levels in NIDDM patients with or without vascular complications. It has been suggested that an acute increase of plasma glucose may produce an oxidative stress in man, and in vitro studies have demonstrated that high glucose and free radicals induce cellular expression of ICAM-1. In this study, three different experiments were performed in nine NIDDM patients and in seven matched healthy controls: oral glucose tolerance test, antioxidant glutathione i.v. administration for two h, oral glucose tolerance test plus glutathione i.v. administration. Blood samples were drawn at -15 min and every 30 min from 0 to 180 min. During the oral glucose tolerance test, circulating ICAM-1 plasma levels significantly increased in both diabetic and normal subjects. Glutathione administration during the oral glucose tolerance test abolished this phenomenon. Glutathione administered alone significantly decreased circulating ICAM-1 plasma levels in diabetic patients, while no effect was observed in the normal subjects. These data suggest that hyperglycemia may induce an increase of circulating ICAM-1 plasma levels through an oxidative stress, and that the antioxidant glutathione counterbalances this effect. These data support the hypothesis of a causal relationship linking hyperglycemia, oxidative stress and atherogenesis in diabetes mellitus.
细胞间黏附分子-1(ICAM-1)是参与动脉粥样硬化形成的最重要的细胞间黏附分子之一。既往研究报道,无论有无血管并发症,非胰岛素依赖型糖尿病(NIDDM)患者循环中ICAM-1血浆水平均升高。有人提出,血浆葡萄糖的急性升高可能在人体内产生氧化应激,并且体外研究已证明高血糖和自由基可诱导ICAM-1的细胞表达。在本研究中,对9例NIDDM患者和7例匹配的健康对照者进行了三项不同的实验:口服葡萄糖耐量试验、静脉注射抗氧化剂谷胱甘肽2小时、口服葡萄糖耐量试验加静脉注射谷胱甘肽。在-15分钟时以及从0至180分钟每30分钟采集血样。在口服葡萄糖耐量试验期间,糖尿病患者和正常受试者循环中ICAM-1血浆水平均显著升高。口服葡萄糖耐量试验期间给予谷胱甘肽可消除这一现象。单独给予谷胱甘肽可显著降低糖尿病患者循环中ICAM-1血浆水平,而在正常受试者中未观察到效果。这些数据表明,高血糖可能通过氧化应激诱导循环中ICAM-1血浆水平升高,并且抗氧化剂谷胱甘肽可抵消这种作用。这些数据支持了高血糖、氧化应激与糖尿病动脉粥样硬化形成之间存在因果关系的假说。